Relative Bioavailability of Phase II and Phase III formulations of AZD0530

Study identifier:D8180C00033

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomised, Open-label, Cross-over, Single Centre Study in Healthy Volunteers to determine the Relative Bioavailability of the Phase III tablet formulation to the Phase II tablet formulation of AZD0530

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD0530

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Nov 2008

Primary Completion Date: -

Study Completion Date: 01 Mar 2009

Study design

Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Alderley Park, United Kingdom

Arms	Assigned Interventions
Experimental: 1	Drug: AZD0530 of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order. Drug: AZD0530 Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=617&filename=CSR-D8180C00033.pdf
Download
CSR-D8180C00033.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Contact Backup

AZD0530 Clinical Trials

AZD0530ClinicalTrialsMailbox@astrazeneca.com

Investigators

Principal Investigator

Raj Chetty

AstraZeneca, Clinical Pharmacology Unit, Alderley Park